Last updated: 11/07/2018 03:23:27
Clinical Evaluation of eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: Clinical Evaluation of eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An extension study of eltrombopag in subjects, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study TRA108109 (NCT00540423)-<Phase III Study>
Trial description: An open-label, dose-adjustment extension study to evaluate the safety and efficacy of eltrombopag for treatment of subjects with ITP who have previously been enrolled in the eltrombopag trial TRA108109 (NCT00540423).
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) within the Indicated Category
Timeframe: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Secondary outcomes:
Percentage of Participants Achieving a Platelet Count Greater than or Equal to 50 Giga Unit (10^9) per Liter (Gi/L) and Less than or Equal to 400 Gi/L
Timeframe: Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)
Median Platelet Counts
Timeframe: Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)
Percentage of Participants with a Given Maximum Number of Weeks of Continuous Platelet Count Evaluation Greater than or Equal to 50 Gi/L and Greater than or Equal to Twice the Baseline Count Categorized by Weeks on Study Medication (Med.)
Timeframe: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Median Number of Maximum Continuous Weeks of Maintaining Platelet Counts Greater than or Equal to 50 Gi/L and Greater than or Equal to Twice the Baseline Count at Three-Month Intervals
Timeframe: 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30 months (13, 26, 39, 52, 65, 78, 91, 104, 117, and 130 weeks)
Percentage of Participants Experiencing Any Bleeding Episode after Dosing with Study Medication
Timeframe: Baseline; Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, and 136; and last visit/early withdrawal visit (up to Day 982)
Percentage of Participants with a Reduction in Use of Baseline Idiopathic Thrombocytopenic Purpura (ITP) Medication
Timeframe: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Percentage of Participants Initiating Rescue Medication/Treatment During On-Therapy
Timeframe: From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)
Interventions:
Drug: Eltrombopag oral tablets
Enrollment:
19
Observational study model:
Not applicable
Primary completion date:
2011-18-02
Time perspective:
Not applicable
Clinical publications:
Katsutani S, Tomiyama Y, Kimura A, Miyakawa Y, Okamoto S, Okoshi Y, Ninomiya H, Kosugi H, Ishii K, Ikeda Y, Hattori T, Katsura K, Kanakura Y. Oral Eltrombopag for up to Three Years is Safe and Well-Tolerated in Japanese Patients With Previously Treated Chronic Immune Thrombocytopenia: An Open-Label, Extension Study. Int J Hematol. 2013;98(3):323-330.
Medical condition
Idiopathic Thrombocytopenic Purpura
Product
eltrombopag
Collaborators
GSK
Study date(s)
May 2008 to February 2011
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
20+ years
Accepts healthy volunteers
No
- Subject has signed and dated written informed consent.
- Subject (>=20 years) diagnosed with ITP.
- Any severe medical condition (cardiac, hepatic or renal disorder) other than chronic ITP. (Note: "Severe" is defined as >= Grade 3 as a rule according to the "Classification of the Severity of Adverse Experiences (PAB/SD Notification No.80, dated 29 June 1992)
- History of suspected or confirmed arterial or venous thrombosis (e.g., myocardial infarction, deep vein thrombosis) within the last 1 year.
Inclusion and exclusion criteria
Inclusion criteria:
- Subject has signed and dated written informed consent.
- Subject (>=20 years) diagnosed with ITP.
- Subject previously enrolled in TRA108109 (NCT00540423) must have completed the treatment and follow-up periods as defined in that protocol.
- Subject has no intercurrent medical event at risk of thrombosis such as thrombophilia.
- Prolongation of prothrombin time and activated partial thromboplastin time (aPTT) must be within 1.2 times the upper limit of the normal range with no history of hypercoagulable state.
- A complete blood count (CBC), within the reference range, with the following exceptions:
- Hemoglobin: patients with haemoglobin level < the lower limit of normal are eligible for inclusion if hemorrhage is present.
- Neutrophil count >= 1,500/L (1.5x10E9/L) is required for inclusion.
- The following clinical chemistries MUST NOT exceed 1.2 times the upper limit of the normal reference range: creatinine, total bilirubin and alkaline phosphatase.
- The following clinical chemistries MUST NOT exceed 2 times the upper limit of the normal reference range: ALT and AST.
- Albumin must be not less than 80% of the lower limit of normal.
- Female subjects must either be:
- of non-childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal ligation or post-menopausal > 1 year), or
- of childbearing potential and have a negative pregnancy test and agree to use contraceptive methods specified in the GSK List of Highly Effective Methods for Avoidance of Pregnancy from two weeks prior to administration of study medication, throughout the study, and 28 days after completion or premature discontinuation from the study:
- Reticulocyte count within the reference range or elevated in case of bleeding.
Exclusion criteria:
- Any severe medical condition (cardiac, hepatic or renal disorder) other than chronic ITP. (Note: "Severe" is defined as >= Grade 3 as a rule according to the "Classification of the Severity of Adverse Experiences (PAB/SD Notification No.80, dated 29 June 1992)
- History of suspected or confirmed arterial or venous thrombosis (e.g., myocardial infarction, deep vein thrombosis) within the last 1 year.
- History of drug/alcohol abuse or dependence within the last 1 year.
- Suspected blood disorder other than ITP.
- Suspected platelet aggregation abnormality.
- Suspected cyclic thrombocytopenia.
- Suspected Evans Syndrome.
- Subjects who met the GSK Liver Stopping Criteria in the previous eltrombopag study TRA108109 (NCT00540423).
- Current or history of HIV infection or hepatitis B virus or hepatitis C virus infections.
- Current malignancy or history of malignancy that was treated with chemotherapy or radiotherapy.
- Female subjects who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period.
- Subjects who are deemed unsuitable for the study by the investigator (or subinvestigator).
- Treatment with an investigational drug within 30 days preceding the first dose of study medication.
- Pre-existing cardiovascular disease, or arrhythmia known to increase the risk of thromboembolic events (e.g. atrial fibrillation).
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2011-18-02
Actual study completion date
2011-18-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website